VKTX241011C70000
- 0.75
- +0.44+141.94%
Viking Therapeutics Newsroom
Oppenheimer Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $138
Oppenheimer Sticks to Their Buy Rating for Viking Therapeutics (VKTX)
Morgan Stanley Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $105
Viking Therapeutics Analyst Ratings
Oppenheimer Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $138
Stifel Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $95
Truist Financial Maintains Viking Therapeutics(VKTX.US) With Buy Rating
BTIG Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $125
Morgan Stanley Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $105
Buy Rating Affirmed for Viking Therapeutics as VK2735 Shows Promising Weight Loss and Safety Profile
Viking Therapeutics Initiated at Overweight by JP Morgan
Viking Therapeutics Analyst Ratings
J.P. Morgan Initiates Viking Therapeutics(VKTX.US) With Buy Rating, Announces Target Price $80
Buy Rating on Viking Therapeutics Backed by Promising Obesity Drug VK-2735 and Market Potential
Truist Financial Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $120
Truist Financial Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Announces Target Price $120
Buy Rating on Viking Therapeutics: A Strategic Opportunity Amid Market Overreaction
Buy Rating on Viking Therapeutics: Promising VK2735 Development and Strategic Advancements
Truist Financial Maintains Viking Therapeutics(VKTX.US) With Buy Rating
Truist Financial Maintains Viking Therapeutics(VKTX.US) With Buy Rating